Technology

NOT A BLACK BOX

The CytoReason Disease Model

The first model to map and compare treatments, patient groups, and disease mechanisms.

NO DATA LEFT BEHIND

The complexity of human disease mandates full use of all available data.

collect

Access ever-growing disease models and get the latest clinical data – from multiple indications and treatments.

capture

Understand the different layers of the disease with innovative tools like cell-level and network analysis.

compare

Manage your portfolio using all relevant comparisons – across patients, indications, and treatments.

UNPACKING THE MODEL

Datasets
& Literature

Build on the latest omics data and cell-focused NLP.

Cell
State

Get each cell's specific regulatory program.

Disease
Progression

Understand what drives disease changes over time.

Clinical
Variation

Understand disease variation between individual patients.

Cell
Composition

Monitor cytometry, single cell and deconvolved expression to retain cellular information.

Inter-cellular
tissue network

Model cell interactions based on biological features in the tissue.​

Treatments

Understand effects of different treatments on disease landscape.

What’s great about it?

The latest and greatest

Created by top immunologists and backed by top-tier publications.

Couldn’t be more specific

Broken down by disease AND tissue, and even by patient population/disease severity.

Inside Out

Every disease layer is linked to its clinical and molecular features, with tools like cell-level and network analysis.

Bigger and better data

Ever-growing and ever-updated with public and proprietary data.

''

It was a pleasure working with the CytoReason team on AI-driven novel target identification for IBD. Pairing CytoReason’s cell-centered AI-technology with Ferring’s deep therapeutic knowledge in IBD resulted in an exciting and fruitful collaboration

''

Araz Raoof

President of Ferring Research Institute and Senior VP Global Drug Discovery & External Innovation

''

It was a pleasure working with the CytoReason team on AI-driven novel target identification for IBD. Pairing CytoReason’s cell-centered AI-technology with Ferring’s deep therapeutic knowledge in IBD resulted in an exciting and fruitful collaboration
Araz Raoof

''

President of Ferring Research Institute and Senior VP Global Drug Discovery & External Innovation

''

“At Sanofi, we seek to describe diseases at the molecular and cellular level to understand the causes underpinning different patient responses to treatments, and to ultimately match the right medicine to the right patient. We are pleased to expand our collaboration with CytoReason and look forward to applying insights from this collaboration as we work to develop new treatments for patients with IBD.”
Emanuele de Rinaldis

''

VP, Global Head of Precision Medicine & Computational Biology, Sanofi R&D

''

We are pleased to be collaborating with CytoReason with their exceptional AI-powered platform, innovative algorithms and deep understanding of complex disease mechanisms. This, combined with Poolbeg’s unique and valuable data has, ultimately, successfully identified multiple novel influenza drug targets[...] Thanks to their ground-breaking technology, we were able to accelerate our research activity, reduce costs, and open up new possibilities for target identification and drug development.
Jeremy Skillington

''

CEO at Poolbeg Pharma

Bring your data to life

Skip to content